Drug
Perampanel
Perampanel: highest development phase Post-Market, developed by Eisai, United Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Eisai, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Perampanel Oral Tablet NCT03457129 | Post-Market | Epilepsy |
| perampanel NCT01527006 | Phase 2 | Central Nervous System |
| Perampanel NCT04497142 | Phase 1/2 | Glioma, Malignant |
| perampanel NCT01240187 | Phase 1 | Partial Onset Epilepsy |
Latest
No recent events.
Follow Perampanel on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.